Amendments to the Claims:

Listing of Claims

This listing of claims replaces all prior versions, and listings, of claims in the application.

Please amend Claims 57, 62, 64, 66, 70, 78- 80, 85, 91, 100 and 101 as follows:

Claims 1-55 (Cancelled).

Claim 56 (Previously Presented) A solid oral dosage form comprising

(a) a compound of the formula (I) or (II):



(I)



(II)

wherein

m is an integer from 0 to 1;

with the proviso that if m is 0 or 1, then

"HET" in the compound of formula (II) is a stable five- or six-membered monocyclic aromatic ring system composed of carbon atoms and one heteroatom, wherein the heteroatom is selected from the group consisting of N, O and S which may occupy any position in the ring whereby the resulting ring system is stable;

A is selected from the group consisting of -C(O)-, SO_2 and CH_2;

Y is selected from the group consisting of CH_2 and CH as part of an olefin;

X is selected from the group consisting of CH_2, CH as part of an olefin, NR_3, S and O;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

Z is selected from the group consisting of N and CH;

R_1 is one to two substituents independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, aminoalkyl and nitro;

Ar is selected from naphthyl, wherein naphthyl is optionally substituted with from one to four substituents independently selected from C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, fluorinated C_1-C_8 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino and C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different); or phenyl, wherein phenyl is optionally substituted with from one to four substituents independently selected from C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, fluorinated C_1-C_8 alkoxy, C_1-C_8 aralkyl (wherein optionally the alkyl or aryl portions are independently substituted and the alkyl portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxyl), C_1-C_8 aralkoxy (wherein optionally the alkoxy or aryl portions are independently substituted and the alkoxy portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxyl), halogen, cyano, hydroxy, amino, nitro, C_1-C_8 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), (halo)$_{1\text{-}3}$(C_1-C_8)alkylthio, C_1-C_8 alkylsulfonyl, C_1-C_8 alkylthio, C_1-C_8 alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from C_1-C_8 alkyl) and phenyl (optionally substituted with from one to two substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, fluorinated C_1-C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl

groups on the amino may be the same or different), C_1-C_4 alkylsulfonyl, C_1-C_4 alkylthio, and C_1-C_4 alkylsulfinyl);

R_2 is selected from the group consisting of NR_4COAr, NR_4CO-heteroaryl, NR_4Ar, CH=CH-Ar, CF=CH-Ar, CH=CF-Ar, CCl=CH-Ar, CH=CCl-Ar, CH=CH-heteroaryl, CF=CH-heteroaryl, CH=CF-heteroaryl, -CCl=CH-heteroaryl, CH=CCl-heteroaryl, OCH_2-Ar, OCH_2-heteroaryl, SCH_2-Ar and NR_4CH_2Ar;

R_3 is selected from the group consisting of hydrogen, acyl, alkyl, alkoxycarbonyl, alkylsulfonyl and arylsulfonyl;

R_4 is selected from the group consisting of hydrogen and C_1-C_4 alkyl;

R_5 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;

and pharmaceutically acceptable salts thereof; and

(b) pharmaceutically acceptable carriers.

Claim 57 (Currently Amended). The solid oral dosage form of Claim 56 wherein "HET" of formula II is selected from the group consisting of thiophene, furan, pyrrole and pyridine;

A is -C(O)-;

Ar is naphthyl, wherein naphthyl is optionally substituted with from one to four substituents independently selected from trifluoromethyl, trifluoromethoxy, -NH-C_1-C_4 alkyl ~~M~~ and -N-(C_1-C_4 alkyl)$_2$ (wherein the alkyl groups on the amino may be the same or different);

R_2 is NR_4COAr;

R_4 is selected from the group consisting of hydrogen and methyl.

Claim 58 (Previously Presented) The solid oral dosage form of Claim 56 wherein R_4 is hydrogen.

Claim 59 (Previously Presented) The solid oral dosage form of Claim 56 wherein the compound is of formula (III):



(III)

wherein

Y is selected from the group consisting of CH_2 and CH as part of an olefin;

X is selected from the group consisting of CH_2, CH as part of an olefin, NR_3, S and O;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

R_1 is one to two substituents independently selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen, amino C_1-C_4 alkyl, ~~oxo~~ and nitro;

R_2 is NHCOAr;

R_3 is selected from the group consisting of hydrogen, acyl, C_1-C_4 alkyl, C_1-C_4 alkylsulfonyl and arylsulfonyl;

R_5 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;

and (b) a pharmaceutically acceptable carrier.

Claim 60 (Previously Presented) The solid oral dosage form of Claim 59 wherein

Y is selected from the group consisting of CH_2 and CH as part of an olefin;

X is selected from the group consisting of CH_2, CH as part of an olefin, O and S;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

A is –C(O)-;

Z is CH;

Ar is phenyl, wherein phenyl is optionally substituted with from one to four substituents independently selected from C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, fluorinated C_1-C_8 alkoxy, C_1-C_8 aralkyl (wherein optionally the alkyl or aryl portions are independently substituted and the alkyl portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxyl), C_1-C_8 aralkoxy (wherein optionally the alkoxy or aryl portions are independently substituted and the alkoxy portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted

with from one to two substituents selected from halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxyl), halogen, cyano, hydroxy, amino, nitro, C_1-C_8 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), (halo)$_{1-3}$(C_1-C_8)alkylthio, C_1-C_8 alkylsulfonyl, C_1-C_8 alkylthio, C_1-C_8 alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from C_1-C_8 alkyl) and phenyl (optionally substituted with from one to two substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, fluorinated C_1-C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_4 alkylsulfonyl, C_1-C_4 alkylthio, and C_1-C_4 alkylsulfinyl);

and (b) a pharmaceutically acceptable carrier.

Claim 61 (Previously Presented) A solid oral dosage form comprising (a) a compound of the formula (IV):



X is selected from the group consisting of CH_2, S and O;

R_1 is one to two substituents independently selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen, amino C_1-C_4 alkyl and nitro;
R_5 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;
R_6 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, phenyl (wherein the phenyl is optionally substituted with from one to two substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, fluorinated C_1-C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_4 alkylsulfonyl, C_1-C_4 alkylthio, and C_1-C_4 alkylsulfinyl); aralkyl (wherein the alkyl or aryl portions are optionally independently substituted and the alkyl portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxyl), aralkoxy (wherein the alkoxy or aryl portions are optionally independently substituted and the alkoxy portion may be substituted with at least one fluorine and/or the aryl portion may be independently substituted with from one to two substituents selected from halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxyl), heteroaryl (optionally substituted with one to two substituents independently selected from C_1-C_4 alkyl and halogen), heteroaryl(C_1-C_8)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents selected from C_1-C_8 alkyl), (halo)$_{1\text{-}3}$(C_1-C_4)alkylthio and halogen; and
R_7 is independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxyl, C_1-C_6 alkyl, C_1-C_6 alkoxy, fluorinated C_1-C_6 alkyl and combinations thereof, wherein R_7 represent one to four independently selected groups; and

(b) pharmaceutically acceptable carrier.

Claim 62 (Currently Amended) The solid oral dosage form of claim 61 wherein the ~~additive~~ carrier is selected from the group consisting of diluents, granulating agents, lubricants, binders, glidants, and disintegrating agents.

Claim 63 (Previously Presented) A solid oral dosage form comprising (a) a compound of formula (IVa):



Formula (IVa)

wherein

Y is selected from the group consisting of CH_2 and CH as part of an olefin;

X is selected from the group consisting of CH_2, CH as part of an olefin, S and O;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

R_5 is one to two substituents independently selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups may be the same or different), trifluoromethyl and trifluoromethoxy; and

(b) pharmaceutically acceptable carrier.

Claim 64 (Currently Amended) The solid oral dosage form of claim ~~61~~ 63 wherein the ~~additive~~ carrier is selected from the group consisting of diluents, granulating agents, lubricants, binders, glidants, and disintegrating agents.

Claim 65 (Previously Presented) A solid oral dosage form comprising (a) a compound of formula (I):



(I)

wherein

A is selected from the group consisting of -C(O)-, SO_2 and CH_2;

Y is selected from the group consisting of CH_2 and CH as part of an olefin;

X is selected from the group consisting of CH_2, CH as part of an olefin, NR_3, S, O and SO_2;

with the proviso that if Y is CH as part of an olefin, then X is CH as part of an olefin;

Z is selected from the group consisting of N and CH;

R_1 is one to two substituents independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, aminoalkyl, and nitro;

R_2 is selected from the group consisting of NR_4COAr, NR_4CO-heteroaryl, NR_4Ar, CH=CH-Ar, CF=CH-Ar, CH=CF-Ar, CCl=CH-Ar, CH=CCl-Ar, CH=CH-heteroaryl, CF=CH-heteroaryl, CH=CF-heteroaryl, -CCl=CH-heteroaryl, CH=CCl-heteroaryl, OCH_2-Ar, OCH_2-heteroaryl, SCH_2-Ar and NR_4CH_2Ar;

R_3 is selected from the group consisting of hydrogen, acyl, alkyl, aralkyl, alkoxycarbonyl, alkylsulfonyl, fluorinated alkyl and arylsulfonyl;

Ar is selected from the group consisting of naphthyl, wherein naphthyl is optionally substituted with from one to four substituents independently selected from the group consisting of C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, fluorinated C_1-C_8 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino and C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different); and phenyl, wherein phenyl is optionally substituted with from one to four substituents independently selected from C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, fluorinated C_1-C_8 alkoxy, C_1-C_8 aralkyl (wherein the alkyl portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents selected from the group consisting of halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxy), C_1-C_8 aralkoxy (wherein the alkoxy portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents selected from the group consisting of halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxy), halogen, cyano, hydroxy, amino, nitro, C_1-C_8 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_8 alkylsulfonyl, C_1-C_8 alkylthio, $(halo)_{1\text{-}3}(C_1\text{-}C_8)$alkylthio, C_1-C_8 alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C_1-C_8 alkyl and halogen), heteroaryl(C_1-C_8)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents independently selected from C_1-C_8 alkyl) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, fluorinated C_1-C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_4 alkylsulfonyl, C_1-C_4 alkylthio and C_1-C_4 alkylsulfinyl);

R_4 is selected from the group consisting of hydrogen and C_1-C_4 alkyl;

R_5 is one to two substituents independently selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, chlorine, fluorine, hydroxy, dialkylamino (wherein the alkyl groups on the amino may be the same or different), trifluoromethyl and trifluoromethoxy;

and (b) a pharmaceutically acceptable carrier.

Claim 66 (Currently Amended) The solid oral dosage form of claim ~~61~~ 65 wherein the ~~additive~~ carrier is selected from the group consisting of diluents, granulating agents, lubricants binders, glidants, and disintegrating agents.

Claim 67 (Previously Presented) The solid oral dosage form of claim 65 wherein A is -C(O)-.

Claim 68 (Previously Presented) The solid oral dosage form compound of claim 65 wherein Z is CH.

Claim 69 (Previously Presented) The solid oral dosage form of claim 65 wherein R_1 is one to two substituents independently selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, and halogen.

Claim 70 (Currently Amended) The solid oral dosage from of claim ~~60~~ 65 wherein R_1 is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, chlorine, and fluorine.

Claim 71 (Previously Presented) The solid oral dosage from of claim 65 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, fluorinated C_1-C_8 alkoxy, C_1-C_8 aralkyl (wherein the alkyl portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents independently selected from the group consisting of halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio

and hydroxy), C_1-C_8 aralkoxy (wherein the alkoxy portion is optionally substituted with at least one fluorine and the aryl portion is optionally substituted with from one to two substituents independently selected from the group consisting of halogen, C_1-C_4 alkyl, C_1-C_6 alkylthio and hydroxy), halogen, cyano, hydroxy, amino, nitro, C_1-C_8 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_8 alkylsulfonyl, C_1-C_8 alkylthio, (halo)$_{1-3}$(C_1-C_8)alkylthio, C_1-C_8 alkylsulfinyl, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C_1-C_8 alkyl and halogen), heteroaryl(C_1-C_8)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents independently selected from C_1-C_8 alkyl) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, fluorinated C_1-C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_4 alkylsulfonyl, C_1-C_4 alkylthio and C_1-C_4 alkylsulfinyl).

Claim 72 (Previously Presented) The solid oral dosage form of claim 65 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C_1-C_8 alkyl, C_1-C_8 alkoxy, fluorinated C_1-C_8 alkyl, halogen, hydroxy, (halo)$_{1-3}$(C_1-C_8)alkylthio, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C_1-C_8 alkyl and halogen) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen and hydroxy).

Claim 73 (Previously Presented) The solid oral dosage from of claim 65 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, halogen, hydroxy, (halo)$_{1-3}$(C_1-C_4)alkylthio, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C_1-C_4 alkyl and halogen) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen and hydroxy).

Claim 74 (Previously Presented) The solid oral dosage from of claim 65 wherein Ar is phenyl optionally substituted with from one to four substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, halogen, hydroxy and $(halo)_{1-3}(C_1$-$C_4)$alkylthio, heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C_1-C_4 alkyl and halogen) and phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen and hydroxy).

Claim 75 (Previously Presented) The solid oral dosage form of claim 65 wherein R_2 is selected from the group consisting of NR_4COAr, NR_4CO-heteroaryl, NR_4Ar, CH=CH-Ar, CF=CH-Ar, CH=CF-Ar, CCl=CH-Ar, CH=CCl-Ar, CH=CH-heteroaryl, CF=CH-heteroaryl, CH=CF-heteroaryl, -CCl=CH-heteroaryl, CH=CCl-heteroaryl and NR_4CH_2Ar.

Claim 76 (Previously Presented) The solid oral dosage form of claim 65 wherein R_2 is selected from NR_4COAr.

Claim 77 (Previously Presented) The solid oral dosage form of claim 65 wherein R_2 is selected from NHCOAr.

Claim 78 (Currently Amended) The ~~compound~~ solid oral dosage of claim 65 wherein R_3 is selected from the group consisting of hydrogen, acyl, C_1-C_8 alkyl, $ar(C_1$-$C_8)$alkyl, C_1-C_8 alkoxycarbonyl, C_1-C_8 alkylsulfonyl, $fluorinated(C_1$-$C_8)$ alkyl and arylsulfonyl.

Claim 79 (Currently Amended) The ~~compound~~ solid oral dosage of claim 65 wherein R_3 is selected from the group consisting of hydrogen, acyl, C_1-C_4 alkyl, $ar(C_1$-$C_4)$alkyl and $trifluoro(C_1$-$C_4)$alkyl.

Claim 80 (Currently Amended) The solid oral dosage form of claim ~~8~~ 65 wherein R_3 is selected from the group consisting of hydrogen, formyl, methyl, isopropyl, benzyl and trifluoroethyl.

Claim 81 (Previously Presented) The solid oral dosage form of claim 65 wherein R_5 is one to two substituents independently selected from the group consisting of hydrogen, methyl, methoxy, chlorine, fluorine, hydroxy, dimethylamino and trifluoromethyl.

Claim 82 (Previously Presented) The solid oral dosage form of claim 61 wherein R_6 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, C_1-C_4 alkoxy, phenyl (wherein the phenyl is optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, fluorinated C_1-C_4 alkyl, fluorinated C_1-C_4 alkoxy, halogen, cyano, hydroxy, amino, nitro, C_1-C_4 alkylamino, C_1-C_4 dialkylamino (wherein the alkyl groups on the amino may be the same or different), C_1-C_4 alkylsulfonyl, C_1-C_4 alkylthio and C_1-C_4 alkylsulfinyl); heteroaryl (optionally substituted with one to two substituents independently selected from the group consisting of C_1-C_4 alkyl and halogen), heteroaryl(C_1-C_8)alkyl (wherein the heteroaryl portion is optionally substituted with one to two substituents independently selected from C_1-C_8 alkyl), (halo)$_{1-3}$(C_1-C_4)alkylthio and halogen.

Claim 83 (Previously Presented) The solid oral dosage form of claim 61 wherein R_6 is selected from the group consisting of hydrogen, C_1-C_4 alkyl, phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, halogen and hydroxy), heteroaryl (optionally substituted with one to two substituents independently selected from C_1-C_4 alkyl), (halo)$_{1-3}$(C_1-C_4)alkylthio and halogen.

Claim 84 (Previously Presented) The solid oral dosage form of claim 61 wherein R_6 is selected from the group consisting of hydrogen, methyl, phenyl (optionally substituted with from one to two substituents independently selected from the group consisting of methyl,

methoxy, fluorine and hydroxy), thienyl (optionally substituted with methyl), difluoromethylthio, fluorine, chlorine and iodine.

Claim 85 (Currently Amended) The ~~compound~~ solid oral dosage of claim 61 wherein R_7 is one to three substituents independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy and fluorinated C_1-C_6 alkyl.

Claim 86 (Previously Presented) The solid oral dosage form of claim 61 wherein R_7 is one to three substituents independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, C_1-C_4 alkyl, C_1-C_4 alkoxy and fluorinated C_1-C_4 alkyl.

Claim 87 (Previously Presented) The solid oral dosage form of claim 61 wherein R_7 is one to three substituents independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, C_1-C_2 alkyl, C_1-C_2 alkoxy and fluorinated C_1-C_2 alkyl.

Claim 88 (Previously Presented) The solid oral dosage form of claim 61 wherein R_7 is one to three substituents independently selected from the group consisting of hydrogen, fluorine, chlorine, iodine, hydroxy, methyl, methoxy and trifluoromethyl.

Claim 89 (Previously Presented) The solid oral dosage form of Claim 56 selected from the group consisting of

10-[4-[[(2-Biphenyl)carbonyl]amino]benzoyl]-10,11-dihydro-5H-piperidino[2,1-c][1,4]benzodiazepine;

10-[4-[[(2-Biphenyl)carbonyl]amino]benzoyl]-10,11-dihydro-5H-(tetrahydropyridino)[2,1-c][1,4]benzodiazepine;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-(4-Hydroxyphenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-4-hydroxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-(3-Hydroxyphenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-5-hydroxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-2-thienyl)-4-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,6-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*R*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[2-methoxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3,4,5-Tetrafluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Chloro-5-trifluoromethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Fluoro-3-chloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(Difluoromethylthio)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[2-hydroxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-hydroxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8-methoxy-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8-fluoro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(9-chloro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8,9-difluoro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8-methyl-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(8-chloro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(8-fluoro-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(10-methyl-1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-3,5-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Iodo-3-methyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-3,5-Dichloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-3-iodo-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(2-Fluoro-phenyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-*N*-[3-dimethylamino-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*S*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

and pharmaceutically acceptable salts thereof.

Claim 90 (Previously Presented) The solid oral dosage form of Claim 65 selected from the group consisting of

(*RS*)-2-(3-Thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Thienyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Thienyl)-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(2-Thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-2-thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-2-thienyl)-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2,2-dioxo-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2-benzyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2-formyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-isopropyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,6-Dimethyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[2-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[2-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-trifluoromethyl-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[2-methyl-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methyl-phenyl)-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-*N*-[4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-(2,2,2-trifluoroethyl)-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3,4,5-Tetrafluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-3-chloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,3-Dichloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2,6-Dichloro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-3-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-4-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-fluoro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methyl-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-methoxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-*N*-[3-hydroxy-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]thiazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Methyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(4-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-(3-Methoxy-phenyl)-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-4-fluoro-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-4-methoxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

(*RS*)-2-Phenyl-5-methoxy-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide;

and pharmaceutically acceptable salts thereof.

Claim 91 (Currently Amended) A method of treating a condition selected from hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim ~~1~~ 56.

Claim 92 (Previously Presented) The method of Claim 91, wherein the condition is congestive heart failure.

Claim 93 (Previously Presented) The method of Claim 91, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

Claim 94 (Previously Presented) A method of treating a condition selected from hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 65.

Claim 95 (Previously Presented) The method of Claim 94, wherein the condition is congestive heart failure.

Claim 96 (Previously Presented) The method of Claim 94, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

Claim 97 (Previously Presented) A method of treating a condition selected from hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 61.

Claim 98 (Previously Presented) The method of Claim 97, wherein the condition is congestive heart failure.

Claim 99 (Previously Presented) The method of Claim 97, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

Claim 100 (Currently Amended) The ~~compound~~ solid dosage form of claim 89 wherein the compound is (*S*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-6*H*-[1,4]oxazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide and pharmaceutically acceptable salts thereof.

Claim 101 (Currently Amended) The ~~compound~~ solid dosage form of claim 90 wherein the compound is (*RS*)-2-Phenyl-*N*-[3-chloro-4-(1,3,4,12a-tetrahydro-2-methyl-6*H*-[1,4]pyrazino[4,3-*a*][1,4]-benzodiazepin-11(12*H*)-yl-carbonyl)phenyl]benzamide and pharmaceutically acceptable salts thereof.